Amit Sachdev, EVP, Chief Patient Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 113,316 shares at $273.59 ($29.9M) on 2020-05-05, disclosed to the SEC on 2020-05-06.
Seasonal sale ($29.9M) by EVP, Chief Patient Officer — this insider has traded VRTX in May in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $258.59 | 1,400 | $362K | 1.2% |
| 2 | $258.59 | 1,400 | $362K | 1.2% |
| 3 | $259.63 | 6,223 | $1.6M | 5.4% |
| 4 | $259.63 | 6,223 | $1.6M | 5.4% |
| 5 | $260.48 | 8,383 | $2.2M | 7.3% |
| 6 | $260.48 | 8,383 |
| $2.2M |
| 7.3% |
| 7 | $261.68 | 4,395 | $1.2M | 3.8% |
| 8 | $261.68 | 4,395 | $1.2M | 3.8% |
| 9 | $262.69 | 9,447 | $2.5M | 8.3% |
| 10 | $262.69 | 9,447 | $2.5M | 8.3% |
| 11 | $263.58 | 964 | $254K | 0.8% |
| 12 | $263.58 | 964 | $254K | 0.8% |
| 13 | $264.92 | 12,940 | $3.4M | 11.5% |
| 14 | $264.92 | 12,940 | $3.4M | 11.5% |
| 15 | $265.72 | 100 | $27K | 0.1% |
| 16 | $267.34 | 300 | $80K | 0.3% |
| 17 | $267.34 | 300 | $80K | 0.3% |
| 18 | $269.08 | 700 | $188K | 0.6% |
| 19 | $270.01 | 11,553 | $3.1M | 10.4% |
| 20 | $270.01 | 11,553 | $3.1M | 10.4% |
| 21 | $271.09 | 100 | $27K | 0.1% |
| 22 | $272.58 | 403 | $110K | 0.4% |
| 23 | $272.58 | 403 | $110K | 0.4% |
| 24 | $273.59 | 200 | $55K | 0.2% |
| 25 | $273.59 | 200 | $55K | 0.2% |
| Total | $264.05 avg | 113,316 | $29.9M | 100% |
| Filing → |
| VRTX | SELL | 2024-05-17 | $14K | — | Filing → |
| VRTX | SELL | 2024-02-27 | $2.6M | — | Filing → |
| VRTX | SELL | 2024-02-23 | $2.7M | — | Filing → |